Group 1 - Sanofi Pharmaceutical announced a subscription agreement with four investors, including Huaxi Biotechnology, to issue approximately 17.35 million new shares at HKD 12 per share, representing about 16.50% of the current issued share capital [2] - The share placement price reflects a discount of approximately 19.84% compared to Sanofi's closing price of HKD 14.97 on September 5 [2] - The total funds raised from this placement are expected to be around HKD 208 million, with a net amount of approximately HKD 206 million [2] Group 2 - Sanofi Pharmaceutical, a pioneer in the nucleic acid drug field in China, has not yet commercialized any products since its establishment in 2007 and is currently facing financial losses [6] - The company reported a net profit loss that narrowed from USD 216 million in 2021 to USD 50 million in 2024, but still recorded a loss of USD 3.49 million in the first half of 2025 [6] - As of June 30, 2025, the company's current assets were only USD 14 million, highlighting the need for sufficient funding to support clinical pipelines and market preparations [6] Group 3 - The core candidate drug STP705 is being developed for two tumor indications and has shown potential in the local fat reduction field, which is of particular interest to Huaxi Biotechnology [3][4] - STP705 has demonstrated excellent safety in early clinical trials, supporting its advancement to the II phase of development [4] - Huaxi Biotechnology's investment is seen as a strategic move to leverage Sanofi's technology platform, particularly in targeted fat reduction applications [7] Group 4 - Huaxi Biotechnology's investment in Sanofi is not merely financial but a strategic positioning in the small nucleic acid and RNAi technology field, with plans for further investment and collaboration if market and technology validation progresses [7] - The investment aims to provide Sanofi with much-needed capital support while opening doors for Huaxi Biotechnology in cutting-edge treatment areas [7] - The success of this partnership will depend on the clinical validation of technology, commercialization capabilities, and the depth of strategic collaboration between the two companies [7] Group 5 - Huaxi Biotechnology has faced growth challenges, with revenue declining from CNY 6.359 billion in 2022 to CNY 5.371 billion in 2024, marking a significant downturn [9] - The company's skin science innovation business, once a revenue pillar, has seen a substantial drop in income, contributing to overall performance issues [10] - The investment in Sanofi is viewed as a strategic response to these pressures, aiming to balance immediate financial needs with long-term innovation goals [12]

Core Viewpoint - The investment in Saint Nor Pharmaceutical is a strategic move for the company to enhance its position in the biopharmaceutical sector, particularly in innovative drug development and to leverage synergies in its core business areas [1][2]. Investment Strategy - The investment amount is approximately HKD 138 million, funded entirely from the company's own resources, and will be paid in installments as per the agreement [2]. - The company recognizes the long development cycles and high risks associated with small nucleic acid drug research and has established risk control and exit arrangements through the investment agreement [2]. Business Development - The company reported a steady increase in sales revenue from its innovative hyaluronic acid products and other bioactive substances, accounting for over 23% of total sales in the first half of 2025 [3]. - Six new bioactive raw material products have been launched, including Hyatrue® cross-linked sodium hyaluronate and BloomColla® recombinant type III humanized collagen [3]. Operational Adjustments - The company has undergone systematic adjustments in its operational philosophy and business direction since March 2025, leading to a significant reduction in sales expense ratio by 12.46 percentage points year-on-year in Q2 [4]. - The focus is on transforming consumer products based on long-term technological barriers and scientific assets, particularly in the fields of cell biology and glycoscience [5]. Organizational Changes - The company is shifting away from hiring external "professional operators" and is instead selecting and training entrepreneurial talents who align with the company's values for management positions [6]. - A one-time management expense of approximately CNY 29 million was incurred during this transition, aimed at laying a solid foundation for long-term development [6]. Scientific Communication - The company is committed to reshaping its scientific image and defending scientific values, aiming to establish a rigorous scientific communication system to counter misinformation in the industry [6].

本 公 告 僅 供 參 考 ， 並不 構 成 收 購、 購 買 或 認 購本 公 司 任 何 證券 的 邀 請 或要 約。 香 港 交易 及 結 算 所 有限 公 司 及 香港 聯 合 交 易 所有 限 公 司 對 本公 告 的 內 容概 不 負 責， 對 其 準 確 性或 完 整 性 亦不 發 表 任 何 聲明 ， 並 明 確 表示 ， 概 不 對因 本 公 告全 部 或 任 何 部份 內 容 而 產生 或 因 倚 賴 該等 內 容 而 引 致的 任 何 損 失承 擔任何責任。 Sirnaomics Ltd. 聖 諾 醫 藥 * 於開曼群島註冊成立的有限公司） （股份代號：2257） 補充公告 根據一般授權認購新股份 本公司財務顧問 茲提述Sirnaomics Ltd.（「本公司」）日期為2025年9月7日的公告（「該公告」）， 內 容 有關 認 購 事 項 。除 另 有 界 定外 ， 本 公 告 所用 詞 彙 與 該 公告 所 界 定 者具 有相同涵義。 本補充公告旨在進一步提供有關認購事項所得款項用途的補充資料。 認購事項所得款項淨額用途 誠如該公告所述，認購事項所得款項總額將約為208.2百萬港元及認 ...

Core Viewpoint - The Chinese beauty industry is experiencing a significant transformation driven by strategic investments in cutting-edge technology and content-driven brands, indicating a shift towards a more integrated and innovative market structure [4][25][28]. Investment Trends - In the first nine months of 2025, Chinese beauty companies completed 13 investments/acquisitions, with disclosed amounts exceeding 5.5 billion RMB, accounting for nearly 60% of the industry's capital flow [4][6]. - Major funding is concentrated in a few leading projects, indicating a selective investment phase, with the top three projects totaling nearly 5.2 billion RMB [6]. - The focus on technology and raw materials is evident, with regenerative medicine and RNA technology becoming key investment areas [7][24]. Strategic Investments - Huaxi Biological's investment in Saintno Pharmaceutical is a prime example of the focus on small nucleic acid drugs, which have significant potential despite the company currently lacking product sales [7][12]. - Proya's investment in Huazhi Xiao aims to build a business ecosystem, leveraging the brand's influence among young consumers and its potential for overseas expansion [10][13]. International Comparison - International giants like L'Oréal and Unilever are also active in the beauty investment space, with L'Oréal completing eight investments and Unilever seven in the first nine months of the year [14][19]. - The investment logic of international players tends to favor acquiring mature brands, while Chinese companies emphasize strategic collaboration and investment in technology [23][24]. Future Outlook - The current investment trends suggest a restructuring of the Chinese beauty industry, moving towards a model supported by technology, content, and global asset integration [25][30]. - The capital influx is raising industry standards, potentially eliminating smaller players lacking differentiation while providing growth opportunities for niche and innovative brands [24][25]. - The evolving landscape indicates that the future of the global beauty industry may be significantly influenced by the capital dynamics within China, potentially leading to the emergence of new world-class beauty giants from the Chinese capital ecosystem [30].

Group 1 - The stock of Sainteno Pharmaceuticals-B (02257.HK) rose over 5% in the afternoon trading session on September 12, 2023 [2] - As of the time of reporting, the stock was up 3.62%, trading at HKD 19.46 [2] - The trading volume reached HKD 32.4354 million [2]

Group 1 - The core point of the article is that 圣诺医药-B (02257) experienced a significant stock price increase, rising over 5% in the afternoon trading session, with a current price of 19.46 HKD and a trading volume of 32.44 million HKD [1] - 圣诺医药-B received a substantial investment from Bloomage Biotechnology (Hong Kong) Limited and its affiliates, acquiring 11.57 million shares valued at approximately 139 million HKD [1] - 华熙生物, through its wholly-owned subsidiary, subscribed to the strategic placement of shares in 圣诺医药 at a price of 12 HKD per share, amounting to about 138 million HKD, resulting in 华熙生物 holding approximately 9.44% of 圣诺医药's total equity post-placement [1] Group 2 - 华熙生物 plans to leverage 圣诺医药's leading advantages in RNAi technology and PNP platform to explore the industrialization of small nucleic acid drugs in targeted fat reduction [1] - The collaboration will focus on discussing clinical development and commercial cooperation for the STP705 targeted fat reduction project, accelerating the layout in the aesthetic medicine sector [1]

Core Viewpoint - Saint Noble Pharmaceuticals-B (02257) experienced a significant increase in stock price, rising over 5% in the afternoon trading session, with a current price of 19.46 HKD and a trading volume of 32.44 million HKD [1] Group 1: Shareholding and Investment - Bloomage Biotechnology (Hong Kong) Limited and its affiliates have acquired 11.57 million shares of Saint Noble Pharmaceuticals, valued at approximately 139 million HKD [1] - Huaxi Biotechnology, through its wholly-owned subsidiary, subscribed to shares in Saint Noble Pharmaceuticals at a price of 12 HKD per share, totaling around 138 million HKD, resulting in a 9.44% ownership stake in the company [1] Group 2: Strategic Collaboration - Huaxi Biotechnology aims to leverage Saint Noble Pharmaceuticals' leading advantages in RNAi technology and PNP platform to explore the industrialization of small nucleic acid drugs in targeted fat reduction [1] - The focus will be on discussing clinical development and commercial cooperation for the STP705 targeted fat reduction project, accelerating the layout in the aesthetic medicine sector [1]

Core Viewpoint - Sanofi Pharmaceutical-B (02257) has seen a significant stock price increase of over 530% this year, with a current price of HKD 22.12 and a trading volume of HKD 33.0162 million [2] Group 1: Stock Performance - Sanofi Pharmaceutical's stock rose by over 9% during the trading session, reflecting strong market interest [2] - The stock has accumulated a year-to-date increase of over 530% [2] Group 2: Investment and Strategic Partnerships - Sanofi Pharmaceutical announced a placement of 17.3524 million new shares at a discount of 19.84% to four investors, including Huaxi Biotechnology (Hong Kong) [2] - Huaxi Biotechnology plans to invest approximately CNY 138 million to acquire shares in Sanofi Pharmaceutical, resulting in a 9.44% ownership stake post-placement [2] - The investment by Huaxi Biotechnology aims to advance Sanofi Pharmaceutical's research and commercialization in the fields of medical aesthetics, aging intervention, and regenerative medicine, particularly focusing on the STP705 targeted fat reduction project and other siRNA-based medical aesthetic assets [2]

Group 1 - The stock price of Saint Noble Pharmaceuticals-B (02257.HK) has increased by over 18%, with a cumulative increase of more than 90% in the month [1] - As of the latest update, the stock is trading at 17.79 HKD, with a trading volume of 45.3042 million HKD [1]

Group 1 - Saint Noble Pharmaceuticals-B (02257.HK) has seen its stock price increase by over 18%, with a cumulative increase of more than 90% in the month [1] - As of the latest update, the stock is trading at 17.79 HKD, with a trading volume of 45.3042 million HKD [1]